|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02637 HAIXI PHARMA
Nominal 
113.300 +0.400 (+0.354%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| ROAA (%) | 20.659% | 23.909% | 16.387% |
| ROAE (%) | 28.752% | 33.896% | 23.970% |
| Return on Capital Employed (%) | 23.718% | 26.424% | 20.848% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Gross Profit Margin (%) | 82.967% | 83.263% | 80.988% |
| EBITDA Margin (%) | 33.277% | 43.314% | 44.572% |
| Pre-tax Profit Margin (%) | 31.926% | 41.945% | 34.718% |
| Net Profit Margin (%) | 29.159% | 37.095% | 32.467% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Current Ratio (X) | 1.902 X | 2.852 X | 3.887 X |
| Quick Ratio (X) | 1.708 X | 2.640 X | 3.572 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Total Liabilities / Total Assets(%) | 28.379% | 27.833% | 31.637% |
| Total Debt / Total Assets (%) | 7.526% | 8.920% | 21.897% |
| Net Debt / Total Assets (%) | 2.461% | -36.370% | -18.838% |
| Total Debt / Shareholders' Funds (%) | 10.508% | 12.360% | 32.030% |
| Long Term Debt / Shareholders' Funds (%) | 5.957% | 9.636% | 14.894% |
| Net Debt / Shareholders' Funds (%) | 3.436% | -50.397% | -27.556% |
| Net Cash / (Debt) ($) | (18.600M) | 204.234M | 79.300M |
| Net Cash / (Debt) per share ($) | -- | -- | -- |
| Total Debt / Capital Employed (%) | 9.914% | 11.269% | 27.859% |
| Interest Coverage Ratio (X) | 21.633 X | 18.142 X | 3.982 X |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Inventory Turnover (Day) | 138.063 Day | 183.120 Day | 256.385 Day |
| Receivables Turnover (Day) | 15.407 Day | 14.769 Day | 10.366 Day |
| Payables Turnover (Day) | 7.269 Day | 3.408 Day | 5.341 Day |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 136,079 |
| %Change | 15.857% |
| EPS / (LPS) | RMB 2.020 |
| NBV Per Share (¥) | RMB -- |